Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesCancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1941887

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1941887

Cancer Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Preventive Cancer Vaccine, Therapeutic Cancer Vaccine), By Indication Type, By Technology Type, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Cancer Vaccine Market Summary

The global cancer vaccine market size was estimated at USD 9.93 billion in 2025 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. This growth is primarily driven by the rising global burden of cancer, increasing adoption of immunotherapy-based treatments, and rapid advancements in vaccine technologies such as mRNA, dendritic cell platforms, and personalized neoantigen vaccines.

The Cancer Vaccine industry is expanding rapidly because of the rising global burden of cancer and the increasing emphasis on immunotherapy as a viable long-term treatment option. Advances in vaccine technology, such as mRNA and DNA platforms, have significantly improved the ability to design vaccines that teach the immune system to recognize cancer-specific antigens and destroy tumor cells more effectively than traditional therapies.

Interest in Cancer Vaccine has been bolstered by growing investment from pharmaceutical companies and academic research groups seeking more personalized treatments that can reduce side effects and improve patient outcomes, especially in solid tumors where options remain limited. For instance, in January 2026, Moderna and Merck reported that their personalized cancer vaccine used with Keytruda showed a sustained reduction in risk of recurrence or death in high-risk melanoma patients during long-term follow-up, reinforcing confidence in vaccine approaches and driving further clinical development and funding.

Another major growth factor in the Cancer Vaccine industry is the rapid pace of scientific innovation improving the precision and effectiveness of vaccine candidates. New techniques in antigen identification, neoantigen targeting, and computational biology have enabled vaccines to be tailored to the unique genetic profile of individual tumors, which is critical for triggering a robust immune response. The expanding pipeline of clinical trials demonstrates increasing confidence among researchers and investors that Cancer Vaccine can deliver meaningful benefits across multiple cancer types, including those historically difficult to treat.

For instance, in July 2025, Scientists at the University of Florida developed an experimental mRNA vaccine that triggered a strong anticancer immune response against tumors in preclinical models, highlighting both the promise of next-generation vaccines and the technological momentum supporting market growth.

Market growth is also propelled by supportive policy environments, increasing public awareness of cancer prevention and early detection, and the integration of novel diagnostic tools that work in tandem with vaccine strategies. Governments and health agencies have intensified funding for immunotherapy research, and collaborations between biotech firms and research institutions are becoming more common, which accelerates product development and regulatory approval pathways.

Moreover, the success of vaccine platforms during the COVID-19 pandemic has reinforced confidence in mRNA technology for other diseases, including cancer, leading to greater investment and quicker translation of research into clinical applications. For instance, in September 2025, Russia announced that its new cancer vaccine Enteromix, developed using advanced mRNA technology, was ready for clinical use and would be provided free to patients following regulatory approval, illustrating both the technological progress and policy support driving market expansion.

Global Cancer Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Cancer Vaccine market report based on vaccine type, indication type, technology type, and region:

  • Vaccine Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Preventive Cancer Vaccine
  • Therapeutic Cancer Vaccine
  • Others
  • Indication Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Other
  • Technology Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant Cancer Vaccine
  • Whole-cell Cancer Vaccine
  • Viral Vector and DNA Cancer Vaccine
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-096-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vaccine Type
    • 1.2.2. Indication Type
    • 1.2.3. Technology Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Cancer Vaccine Market: Vaccine Type Business Analysis

  • 4.1. Vaccine Type Market Share, 2025 & 2033
  • 4.2. Vaccine Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Vaccine Type, 2021 to 2033 (USD Million)
  • 4.4. Preventive Cancer Vaccine
    • 4.4.1. Preventive Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 4.5. Therapeutic Cancer Vaccine
    • 4.5.1. Therapeutic Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Vaccine Market: Indication Type Business Analysis

  • 5.1. Indication Type Market Share, 2025 & 2033
  • 5.2. Indication Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication Type, 2021 to 2033 (USD Million)
  • 5.4. Prostate Cancer
    • 5.4.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 5.5. Bladder Cancer
    • 5.5.1. Bladder Cancer Market, 2021 - 2033 (USD Million)
  • 5.6. Melanoma
    • 5.6.1. Melanoma Market, 2021 - 2033 (USD Million)
  • 5.7. Cervical Cancer
    • 5.7.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
  • 5.8. Other
    • 5.8.1. Other Market, 2021 - 2033 (USD Million)

Chapter 6. Cancer Vaccine Market: Technology Type Business Analysis

  • 6.1. Technology Type Market Share, 2025 & 2033
  • 6.2. Technology Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by technology type, 2021 to 2033 (USD Million)
  • 6.4. Recombinant Cancer Vaccine
    • 6.4.1. Recombinant Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.5. Whole-cell Cancer Vaccine
    • 6.5.1. Whole-cell Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.6. Viral Vector and DNA Cancer Vaccine
    • 6.6.1. Viral Vector and DNA Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.7. Other Technologies
    • 6.7.1. Other Technologies Market, 2021 - 2033 (USD Million)

Chapter 7. Cancer Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Cancer Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Technology Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Technology Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Technology Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Technology Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Technology Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Technology Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Technology Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Technology Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Technology Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Technology Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Technology Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Technology Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Technology Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Technology Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Technology Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Technology Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Technology Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Technology Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Technology Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Technology Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Technology Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Technology Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Technology Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GSK plc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Dendreon Pharmaceuticals LLC.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dynavax Technologies.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Ferring B.V.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Amgen, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Moderna, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Sanofi
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. AstraZeneca
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bristol-Myers Squibb Company
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-096-2

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Cancer Vaccine market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 5 Global Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 6 Global Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 7 North America Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 9 North America Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 10 North America Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 11 U.S. Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 15 Canada Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 24 UK Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 25 UK Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 26 UK Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 28 Germany Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 29 Germany Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 30 France Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 31 France Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 32 France Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 33 Italy Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 34 Italy Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 35 Italy Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 36 Spain Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 37 Spain Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 38 Spain Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 39 Norway Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 40 Norway Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 41 Norway Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 42 Denmark Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 43 Denmark Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 44 Denmark Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 45 Sweden Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 46 Sweden Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 47 Sweden Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Cancer Vaccine market, by indication type, 2021 - 2033 (USD
  • Table 51 Asia Pacific Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 52 Japan Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 53 Japan Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 54 Japan Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 55 China Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 56 China Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 57 China Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 58 India Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 59 India Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 60 India Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 61 Australia Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 62 Australia Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 63 Australia Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 64 South Korea Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 65 South Korea Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 66 South Korea Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 67 Thailand Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 68 Thailand Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 69 Thailand Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 70 Latin America Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 73 Latin America Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 74 Brazil Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 76 Brazil Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 77 Argentina Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 79 Argentina Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 84 South Africa Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 86 South Africa Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 90 UAE Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 91 UAE Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 92 UAE Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cancer Vaccine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Cancer Vaccine market dynamics
  • Fig. 11 Cancer Vaccine market: Porter's five forces analysis
  • Fig. 12 Cancer Vaccine market: PESTLE analysis
  • Fig. 13 Vaccine Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Preventive Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 15 Therapeutic Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 16 Others market, 2021 - 2033 (USD Million)
  • Fig. 17 Indication Type market, 2021 - 2033 (USD Million)
  • Fig. 18 Prostate Cancer market, 2021 - 2033 (USD Million)
  • Fig. 19 Bladder Cancer market, 2021 - 2033 (USD Million)
  • Fig. 20 Melanoma market, 2021 - 2033 (USD Million)
  • Fig. 21 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 22 Other market, 2021 - 2033 (USD Million)
  • Fig. 23 Technology Type market, 2021 - 2033 (USD Million)
  • Fig. 24 Recombinant Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 25 Whole-cell Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 26 Viral Vector and DNA Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 27 Other Technologies market, 2021 - 2033 (USD Million)
  • Fig. 28 Cancer Vaccine market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!